However, salvage therapy does not always indicate that there is no hope. It is not the same thing as hospice care (comfort ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...

With advances in antiretroviral therapy, people living with HIV can expect to live longer and healthier than ever before if ...

The global hepatitis B diagnostic tests market is on the brink of significant expansion, driven by a surge in disease incidence, heightened awareness campaigns, and rapid advancements in diagnostic ...

Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...

Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...